“美女董秘”上任11天就闪电辞职，一场阵痛而已？

Core Viewpoint - The sudden resignation of Gao Yingying, the newly appointed secretary of the board at Ruizhi Pharmaceutical, after only 11 days in office, raises concerns about the company's internal environment and governance issues [1][3][4]. Group 1: Company Background - Ruizhi Pharmaceutical is located in Yuexiu District, Guangzhou, and primarily engages in the research and production of biological and chemical drugs [8]. - The company has experienced significant turmoil in its leadership, with multiple changes in the actual controller and chairman, leading to instability [4][6]. Group 2: Executive Changes - Since 2021, at least eight core executives, including the general manager and CFO, have resigned, impacting strategic continuity and team stability [6]. - Gao Yingying's predecessor, Xu Jian, also faced challenges, including regulatory scrutiny and early resignation due to compliance issues [7]. Group 3: Financial Performance - The company's revenue from 2019 to 2024 showed fluctuations, with figures of 13.28 billion, 14.82 billion, 16.91 billion, 13.27 billion, 11.38 billion, and 9.7 billion respectively [8]. - In the first three quarters of 2025, Ruizhi Pharmaceutical achieved a revenue of 8.17 billion, a year-on-year increase of 13.68%, while net profit reached 7.09 million, up 111.5% [8]. Group 4: Market Reaction - The stock price of Ruizhi Pharmaceutical saw a significant increase of over 100% in 2025 but began to decline after reaching a peak of 15.28 yuan per share in July, falling to around 9.48 yuan by mid-December [8].